133852Feasibility study of a high-performance data analytics pipeline for highly stratified approach to cardiovascular diseaseClosedFeasibility StudiesISCF"PlaqueTec has an advanced medical catheter that can detect biological signalling directly at the site of coronary artery disease. In clinical use it has shown that intracoronary biomarkers (i) differ depending on the state of disease ii) differ from patient to patient and iii) differ to systemic biomarker levels (i.e. those detected in standard blood sample). Leading clinicians recognise the potential for PlaqueTec's platform to enable personalised treatment strategies. PlaqueTec is now preparing to support investigator led studies (ILS) where clinicians and researchers (both industrial and academic) can access PlaqueTec's technology and data to help better diagnose and treat their patients. PlaqueTec's strategy, via a programme of investigator led studies, is to build world's most comprehensive database of coronary artery disease biomarkers. PlaqueTec will use machine learning and data science within a unique portal that will allow any patient's biomarker ""profile"" to be uploaded and assessed against the most meaningful patient cohorts to a) initially provide a more ""contextualised"" assessment of patient risk and b) ultimately predict therapeutic strategies most likely to offer benefit based on real world evidence. PlaqueTec's immediate challenge is to efficiently develop a scaleable, cloud based digital health system that can curate, analyse and output ""real world"" ILS data in a manner that delivers maximum utility to all potential stakeholders (clinicians, patients, regulators, therapy providers, governments and insurance companies). This feasibility project's objectives/questions: * **What functionality**: Engage with clinicians/stakeholders to define the key functionality of digital health system through which PlaqueTec will commercialise its services; * **What architecture**: Recommend and specify the analytics solution architecture that is best suited to meeting the stakeholder requirements; * **Best machine learning approach**: Identify the best data science and machine learning strategy given the composition of the PlaqueTec database. The enclosed project enables PlaqueTec to i) engage with potential end users and define requirements ii) work with Agile development and data science experts to develop a portal demonstrator and iii) test the ability of the portal demonstrator to answer stakeholder questions based on current datasets. The project will deliver a cloud-based architecture that can be rapidly scaled to provide commercial services to PlaqueTec's planned ILS programme. Innovation: today the treatment of coronary heart disease lacks precision. Massive progress has been made against cancer because patients are given highly specific/targeted treatments based on better biological profiling of their disease. This innovation aims to translate the same approach to coronary heart disease."